Drug safety “virtual” surveillance sought by FDA
Executive Summary
FDA will hold a public meeting to examine the feasibility of public-private partnerships to create a "virtual" product safety surveillance system based on existing datasets and collection activities. Topics will include the creation of "dynamic feedback loops" in which practitioners and patients fuel data collection and are provided with updated information after analysis. FDA is planning to devote user fee resources to overhaul its postmarketing surveillance efforts (1"The Pink Sheet" Jan. 15, 2007, p. 3). The meeting on the "Sentinel Network" will take place March 7-8 at the University System of Maryland Shady Grove Center in Rockville, Md...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.